Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 22, 2019

Merck to buy Peloton Therapeutics in £1.72bn deal

Merck has signed an agreement to acquire Peloton Therapeutics, a US-based clinical-stage biopharmaceutical firm, in a deal valued at around $2.2bn (£1.72bn).

Image: Merck has agreed to acquire US-based clinical-stage biopharmaceutical firm Peloton Therapeutics. Photo: courtesy of Adam Radosavljevic / Pixabay.